R Borrow, R Abad, C Trotter, FRM van der Klis… - Vaccine, 2013 - Elsevier
Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate (MCC) vaccines and the implementation of national vaccination programmes, the incidence …
MJ Knol, SJM Hahné, J Lucidarme… - The Lancet Public …, 2017 - thelancet.com
Background Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly in the UK because of a single strain (the so-called original UK strain) …
JDM Verberk, RA Vos, L Mollema, J van Vliet… - BMC infectious …, 2019 - Springer
Background This paper outlines the methodology, study population and response rate of a third large Dutch population-based cross-sectional serosurvey carried-out in 2016/2017 …
The annual incidence rate of serogroup W invasive meningococcal disease in the Netherlands increased from< 0.05/100,000 (n< 10) before 2015 to 0.5/100,000 (n= 80) in …
MW Bijlsma, MC Brouwer, L Spanjaard… - Clinical Infectious …, 2014 - academic.oup.com
Background. Vaccination with meningococcal serogroup C (MenC) conjugate (MCC) polysaccharide vaccines led to a substantial decline in MenC disease in the vaccinated and …
Background. Several countries consider the implementation of a meningococcal serogroup B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for …
Vaccines have revolutionized public health, preventing millions of deaths each year, particularly in childhood. Yet, there is considerable variability in the magnitude and …
Objective: Recently, a vaccine with the capacity to protect against serogroup B meningococcal (MenB) disease received a positive opinion of the European Medicines …
DA Ishola Jr, R Borrow, H Findlow… - Clinical and Vaccine …, 2012 - Am Soc Microbiol
Serogroup C meningococcal disease incidence and carriage declined rapidly in the United Kingdom after infant serogroup C conjugate vaccination was introduced in 1999, with catch …